Browsing by Author "Hamm, Bernd"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- ItemAssessment of Albumin ECM Accumulation and Inflammation as Novel In Vivo Diagnostic Targets for Multi-Target MR Imaging(2021) Möckel, Jana; Brangsch, Julia; Reimann, Carolin; Kaufmann, Jan O.; Sack, Ingolf; Mangarova, Dilyana B.; Avan, Kader; Taupitz, Matthias; Adams, Lisa C.; Keller, Sarah; Antje, Ludwig; Hamm, Bernd; Botnar, René Michael; Makowski, Marcus R.
- ItemDual-probe molecular MRI for the in vivo characterization of atherosclerosis in a mouse model : Simultaneous assessment of plaque inflammation and extracellular-matrix remodeling(2019) Reimann, Carolin; Brangsch, Julia; Kaufmann, Jan Ole; Adams,Lisa C.; Onthank, David C.; Thöne Reineke, Christa; Robinson, Simon P.; Hamm, Bernd; Botnar, René Michael; Makowski, Marcus R.
- ItemMolecular MR-Imaging for Noninvasive Quantification of the Anti-Inflammatory Effect of Targeting Interleukin-1β in a Mouse Model of Aortic Aneurysm(SAGE Publications Inc., 2020) Brangsch, Julia; Reimann, Carolin; Kaufmann, Jan Ole; Adams, Lisa Christine; Hamm, Bernd; Makowski, Marcus Richard; Thöne-Reineke, Christa; Wilke, Marco; Weller, Michael; Onthank, David; Robinson, Simon; Buchholz, Rebecca; Karst, Uwe; Botnar, Rene MichaelMolecular-MRI is a promising imaging modality for the assessment of abdominal aortic aneurysms (AAAs). Interleukin-1β (IL-1β) represents a new therapeutic tool for AAA-treatment, since pro-inflammatory cytokines are key-mediators of inflammation. This study investigates the potential of molecular-MRI to evaluate therapeutic effects of an anti-IL-1β-therapy on AAA-formation in a mouse-model. Methods: Osmotic-minipumps were implanted in apolipoprotein-deficient-mice (N = 27). One group (Ang-II+01BSUR group, n = 9) was infused with angiotensin-II (Ang-II) for 4 weeks and received an anti-murine IL-1β-antibody (01BSUR) 3 times. One group (Ang-II-group, n = 9) was infused with Ang-II for 4 weeks but received no treatment. Control-group (n = 9) was infused with saline and received no treatment. MR-imaging was performed using an elastin-specific gadolinium-based-probe (0.2 mmol/kg). Results: Mice of the Ang-II+01BSUR-group showed a lower aortic-diameter compared to mice of the Ang-II-group and control mice (p < 0.05). Using the elastin-specific-probe, a significant decrease in elastin-destruction was observed in mice of the Ang-II+01BSUR-group. In vivo MR-measurements correlated well with histopathology (y = 0.34x-13.81, R2 = 0.84, p < 0.05), ICP-MS (y = 0.02x+2.39; R2 = 0.81, p < 0.05) and LA-ICP-MS. Immunofluorescence and western-blotting confirmed a reduced IL-1β-expression. Conclusions: Molecular-MRI enables the early visualization and quantification of the anti-inflammatory-effects of an IL-1β-inhibitor in a mouse-model of AAAs. Responders and non-responders could be identified early after the initiation of the therapy using molecular-MRI.
- ItemNoninvasive Imaging of Endothelial Damage in Patients With Different HbA(1c) Levels : A Proof-of-Concept Study(2019) Engel, Leif-Christopher; Landmesser, Ulf; Goehler, Alexander; Gigengack, Kevin; Wurster, Thomas-Heinrich; Manes, Costantina; Girke, Georg; Jaguszewski, Milosz; Skurk, Carsten; Botnar, René Michael; Leistner, David M.; Lauten, Alexander; Schuster, Andreas; Noutsias, Michel; Hamm, Bernd; Bigalke, Boris; Makowski, Marcus R.
- ItemSimultaneous [18F]fluoride and gadobutrol enhanced coronary positron emission tomography/magnetic resonance imaging for in vivo plaque characterization(Oxford University Press, 2022) Wurster, Thomas H.; Landmesser, Ulf; Abdelwahed, Youssef S.; Skurk, Carsten; Morguet, Andreas; Leistner, David M.; Froehlich, Georg; Haghikia, Arash; Engel, Leif Christopher; Botnar, René Michael; Schuster, Andreas; Noutsias, Michel; Schulze, Daniel; Hamm, Bernd; Furth, Christian; Brenner, Winfried; Bigalke, Boris; Makowski, Marcus R.Aims F-18-sodium fluoride ([18F]fluoride) and gadobutrol are promising probes for positron emission tomography (PET) and magnetic resonance imaging (MRI) characterizing coronary artery disease (CAD) activity. Unlike [18F]fluoride-PET/computed tomography (CT), the potential of PET/MR using [18F]fluoride and gadobutrol simultaneously, has so far not been evaluated. This study assessed feasibility and diagnostic potential of [18F]fluoride and gadobutrol enhanced dual-probe PET/MR in patients with CAD. Methods and results Twenty-one patients (age, 66.7 +/- 6.7 years) with CAD scheduled for invasive coronary angiography (XCA) underwent simultaneous [18F]fluoride (mean activity/effective dose: 157.2 +/- 29.7 MBq/3.77 +/- 0.72 mSv) and gadobutrol enhanced PET/MR on an integrated PET/MRI (3 T) scanner. Optical coherence tomography (OCT) was used as reference. Target-to-background ratio (TBR, [18F]fluoride-PET) and contrast-to-noise ratio (CNR) values (MRI, gadobutrol) were calculated for each coronary segment. Previously suggested PET/CT-TBR thresholds for adverse coronary events were evaluated. High-risk plaques, i.e. calcified and non-calcified thin-cap fibroatheromas (TCFAs) were predominantly located in segments with a TBR >1.28 (P = 0.012). Plaques containing a lipid core on OCT, were more frequently detected in segments with a TBR >1.25 (P < 0.001). TBR values significantly correlated with maximum calcification thickness (P = 0.009), while fibrous cap thickness was significantly less in segments with a TBR >1.28 (P = 0.044). Above a TBR threshold of >1.28, CNR values significantly correlated with the presence of calcified TCFAs (P = 0.032). Conclusion Simultaneous [18F]fluoride and gadobutrol dual-probe PET/MRI is feasible in clinical practice and may facilitate the identification of high-risk patients. The combination of coronary MR-derived CNR values post gadobutrol and [18F]fluoride based TBR values may improve identification of high-risk plaque features.